Compare RAY & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAY | MYNZ |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | Hong Kong | Germany |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 10.2M |
| IPO Year | 2024 | 2021 |
| Metric | RAY | MYNZ |
|---|---|---|
| Price | $4.19 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 81.4K | ★ 402.7K |
| Earning Date | 07-24-2026 | 09-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $9,391,194.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | $5.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $0.60 |
| 52 Week High | $58.88 | $7.80 |
| Indicator | RAY | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 32.15 |
| Support Level | $3.81 | $0.70 |
| Resistance Level | $4.47 | $1.37 |
| Average True Range (ATR) | 0.40 | 0.13 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 65.03 | 25.97 |
Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Men's Care and Women's Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; neck care series; nail care series; tooling and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, handy fan and others. Raytech manufactures products under OEM and ODM.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.